Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ...

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Health Canada has granted a Notice of Compliance (NOC) for Enhertu® (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis ...

Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.

Two phase 3 trials suggest that the antibody drug conjugate led to significantly improved outcomes in both the neoadjuvant ...

Daiichi Sankyo Company, Limited ( OTCPK:DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions October 21, 2025 8:00 AM EDT ...

Shimadzu Asia Pacific joins the global celebration of Shimadzu Corporation's 150th anniversary, marking a century and a half of pioneering innovations that have shaped science, technology, and ...

Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it has entered into a research ...

BERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to take the middle 5.6-mg/kg dose into the phase 3 part of the trial. The ORR ...